MediWound Ltd. filed a Form 6-K on November 5, 2026, disclosing the terms of an underwritten public offering of ordinary shares entered into on November 3, 2026, with H.C. Wainwright & Co., LLC serving as underwriter.

Key Highlights

  • Base offering size: 1,200,000 ordinary shares priced at $12.50 per share, with the underwriter purchasing at $12.09 per share, reflecting a blended underwriting discount.
  • Overallotment exercised in full: The underwriter exercised its 30-day option on November 4, 2026, adding 180,000 ordinary shares on the same terms.
  • Expected gross proceeds: Approximately $17.25 million before deducting underwriting discounts, commissions, and estimated offering expenses, according to the filing.
  • Use of proceeds: The company disclosed it intends to use net proceeds "primarily for working capital and general corporate purposes."
  • Lock-up period: The company and each of its directors and executive officers agreed to a lock-up through the 60th day following the date of the final prospectus supplement, subject to certain exceptions.
  • Underwriter expense reimbursement: The company agreed to reimburse the underwriter $100,000 for legal counsel fees, $25,000 for non-accountable expenses, and $15,950 for clearing costs, with a potential one-time performance bonus of up to $500,000.

MediWound's November 2026 Share Offering: Terms and Structure

According to the filing, MediWound Ltd. (NASDAQ:MDWD) entered into an underwriting agreement with H.C. Wainwright & Co., LLC on November 3, 2026, covering the issuance and sale of 1,200,000 ordinary shares, par value NIS 0.07 per share, at a public offering price of $12.50 per share. The underwriter agreed to purchase those shares at $12.09 per share. The offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-285908), filed with the SEC on March 19, 2025 and declared effective on March 27, 2025.

The filing disclosed that the underwriter exercised its full overallotment option on November 4, 2026, adding 180,000 ordinary shares, bringing the total offering to 1,380,000 shares. The expected gross proceeds from the combined offering, including the option shares, are approximately $17.25 million before deducting underwriting discounts, commissions, and estimated offering expenses payable by the company. The offering was expected to close on or about November 5, 2026, subject to customary closing conditions.

The underwriting agreement contains customary representations, warranties, indemnification obligations, and conditions to closing, the filing stated. In addition to the expense reimbursements described above, the company may at its sole discretion pay the underwriter a one-time performance bonus of up to $500,000. The filing was signed by Hani Luxenburg, Chief Financial Officer, on November 5, 2026.

What Was Disclosed

MediWound disclosed the terms of a November 2026 public offering of 1,380,000 ordinary shares at $12.50 each, with expected gross proceeds of approximately $17.25 million, a 60-day lock-up for the company and its directors and executive officers, and specified underwriter expense reimbursements.